Full history for every metric is available with a Kvantra account
Kezar Life Sciences, Inc. (KZR)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 7 | 0 | 0 | 0 |
| Operating profit | $m | -52 | -42 | |||||
| Net profit | $m | -42 | -55 | -68 | -102 | -84 | -56 | -45 |
| EPS reported | $ | -7.66 | -6.17 | |||||
| Operating cashflow per share | $ | -7.08 | -5.72 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -7.08 | -5.72 | |||||
| Free cash flow | $m | -52 | -42 | |||||
| Net debt | $m | -72 | -66 | |||||
| Book value equity | $m | 70 | 65 | |||||
| Book value per share | $ | 9.58 | 8.88 | |||||
| Number of shares | m | 7.32 | 7.34 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.66 | 0.83 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.89 | -1.28 | |||||
| EV/EBITDA LTM | x | 0.46 | 0.39 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -121.75% | -84.49% | |||||
| FCF Yield | % | -112.52% | -78.04% | |||||
| Quality | ||||||||
| ROE | % | -79.96% | -58.35% | |||||
| ROIC | % | -72.20% | -63.08% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -22.26 | -31.04 | |||||
| Net Debt/EBITDA | x | 1.35 | 2.04 | |||||
| EBIT/Net interest | x | 0.00 | -50.01 | |||||
| Net debt/market cap | % | -156.18% | -122.97% | |||||
| Net debt/Equity | x | -1.03 | -1.02 | |||||
| Gross debt/equity | x | 0.03 | 0.02 | |||||
Company overview
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free